| Literature DB >> 35276385 |
Tuba Reçber1, Selin Seda Timur2, Sevilay Erdoğan Kablan1, Fatma Yalçın3, Tutku Ceren Karabulut4, R Neslihan Gürsoy2, Hakan Eroğlu2, Sedef Kır1, Emirhan Nemutlu5.
Abstract
Antiviral drugs have gained much more attention in recent years due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and many drug candidates are currently under investigation in order to end pandemic. Molnupiravir, a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, is one of the promising candidates for SARS-CoV-2 treatment. In this study, a RP-HPLC method was developed for the determination of Molnupiravir and applied for in vitro permeability studies of self-emulsifying drug delivery system (SEDDS) formulations using Caco-2 cell line. Discovery® HS C18 Column (75 ×4.6 mm, 3 µm) was used at 30 °C. Isocratic elution was performed with ACN:water (20:80 v/v) mixture. The flow rate was 0.5 mL/min and UV detection was at 240 nm. Molnupiravir eluted within 5 min. Molnupiravir was exposed to thermal, photolytic, hydrolytic, and oxidative stress conditions. Peak homogeneity data of Molnupiravir in the stressed samples peak obtained using photodiode array detector, in the stressed sample chromatograms, demonstrated the specificity of the method for their estimation in presence of degradants. The developed method was validated according to the International Council for Harmonisation (ICH) guidelines and found to be linear within the range 0.1-60.0 μg/mL. The method was simple, rapid, selective, sensitive, accurate, precise, robust and rugged. Thus, it was applied successfully for permeability quantitation of Molnupiravir in nanoformulations. The apparent permeability of Molnupiravir in SEDDS formulations, which have droplet size under 350 nm, was calculated as 3.20 ± 0.44 × 10-6 cm/s.Entities:
Keywords: COVID-19; Molnupiravir; Optimization; Permeability; RP-HPLC; Validation
Mesh:
Substances:
Year: 2022 PMID: 35276385 PMCID: PMC8881887 DOI: 10.1016/j.jpba.2022.114693
Source DB: PubMed Journal: J Pharm Biomed Anal ISSN: 0731-7085 Impact factor: 3.571
Fig. 1Chemical structure of MLP.
Fig. 3Chromatograms obtained under optimum chromatographic conditions; a) blank for MLP b) MLP standard spiked matrix at LOQ (0.10 μg/mL) concentration c) MLP standard solution (20 µg/mL).
Forced degradation results of MLP.
| Conditions | Thermal degradation | Oxidative degradation | Acid hydrolysis | Alkali hydrolysis | Photolytic degradation |
|---|---|---|---|---|---|
| Temperature | 80 °C | 40 °C | 40 °C | 25 °C | 25 °C |
| Time | 2 h | 15 min | 2 h | 2 min | 24 h |
| Recovery (%) | 98.8 | 93.7 | 81.8 | 65.2 | 84.0 |
| Peak purity index | 0.9998 | 0.9997 | 0.9997 | 0.9908 | 0.9991 |
Fig. 2Forced degradation study of MLP; a) 80 °C for 2 h, b) 3% H2O2 at 40 °C for 15 min, c) 0.1 M NaOH at room temperature for 2 min, d) 0.01 M NaOH at room temperature for 2 min, e) 0.1 M HCI at 40 °C for 2 h, f) UV light at room temperature for 24 h.
Intra- and inter-day accuracy and precision of the developed method.
| Concentration (μg/mL) | Intra-day (n = 6) | Inter-day (n = 6) | ||
|---|---|---|---|---|
| Accuracy (RE | Precision (RSD | Accuracy (RE, %) | Precision (RSD, %) | |
| 0.1 | -2.02 | 1.89 | 1.78 | 1.90 |
| 1.0 | -1.98 | 1.07 | -1.32 | 2.06 |
| 10.0 | -1.90 | 0.62 | -0.77 | 1.91 |
| 50.0 | -0.38 | 0.92 | -0.13 | 0.96 |
RE, relative error.
RSD, relative standard deviation
The parameters and their levels for robustness study.
| Parameters | Level | ||
|---|---|---|---|
| -1 | 0 | +1 | |
| 19 | 20 | 21 | |
| 0.495 | 0.500 | 0.505 | |
| 29 | 30 | 31 | |
The experimental design and results for robustness study.
| Exp. no | ACN % | Flow rate (mL/min) | Temperature (°C) | Peak area (n = 3) |
|---|---|---|---|---|
| 1 | -1 | -1 | -1 | 377,505 |
| 2 | +1 | -1 | -1 | 381,399 |
| 3 | -1 | +1 | -1 | 365,307 |
| 4 | +1 | +1 | -1 | 378,373 |
| 5 | -1 | -1 | +1 | 365,453 |
| 6 | +1 | -1 | +1 | 411,689 |
| 7 | -1 | +1 | +1 | 358,608 |
| 8 | +1 | +1 | +1 | 380,554 |
| 9 | 0 | 0 | 0 | 411,043 |
| p values | 0.150 | 0.337 | 0.795 |
The characteristics of prepared SEDDS formulations used in transport studies.
| Droplet size (nm) | Polydispersity index | Zeta potential (mV) | Apparent permeability (cm/s) | |
|---|---|---|---|---|
| Blank formulations | 249.9 ± 2.9 | 0.218 ± 0.016 | -1.83 ± 0.07 | – |
| MLP containing formulations | 315.7 ± 8.9 | 0.233 ± 0.003 | 0.46 ± 0.04 | 3.20 × 10−6 ± 0.44 × 10−6 |